Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by westcoast1000on Aug 12, 2023 7:25pm
173 Views
Post# 35585619

RE:RE:RE:General comments, leading to Monday am N.R. Etc

RE:RE:RE:General comments, leading to Monday am N.R. Etc Fox,

The audience for this talk was the Cannacord investors, who are not who we really need anyway.

Monday is a more formal talk. But I am not holding out much hope.

Again, sell the freaking company already!

Uncartainties (like competitors being successful) can get you and hurt you in this world. 

As an aside, I have only been confident in the company over the last two years because of our  stellar clinical results and the development of a scientific understanding of the MOA

. The results, combined with the intelligence we get from Noteable on the market for these assets and the context of BP needing assets, suggests we must be getting a lot of interest and offers. They must be holding out for top dollar, Immunomedics level.  That is a big gamble with our assets. 


<< Previous
Bullboard Posts
Next >>